Moleculin Biotech (MBRX) Change in Cash (2016 - 2025)
Moleculin Biotech (MBRX) posted quarterly Change in Cash of $2.2 million for Q4 2025, up 142.42% year-over-year from $897194.1 in Q4 2024, and up 354.68% quarter-over-quarter from -$854000.0 in Q3 2025.
Moleculin Biotech (MBRX) Change in Cash (2016 - 2025) Analysis & Trends
Moleculin Biotech's Change in Cash history runs 10 years deep, the most recent figure standing at $2.2 million for Q4 2025.
- In Q4 2025, Change in Cash rose 142.42% year-over-year to $2.2 million; the TTM figure through Dec 2025 stood at $4.6 million (up 123.87% YoY), while the FY2025 annual figure was $4.6 million, up 123.87% from the prior year.
- Change in Cash for Q4 2025 stood at $2.2 million, up from -$854000.0 in the prior quarter.
- The five-year high for Change in Cash was $71.1 million in Q1 2021, with the low at -$8.1 million in Q2 2022.
- The 5-year median for Change in Cash is -$4.9 million (2022), against an average of -$314750.0.
- The sharpest annual moves came in 2021 and 2024: Change in Cash jumped 7681.18% in 2021, then sank 398.25% in 2024.
- Moleculin Biotech's Change in Cash stood at -$4.3 million in 2021, then plunged by 69.52% to -$7.2 million in 2022, then soared by 85.8% to -$1.0 million in 2023, then plunged by 398.25% to -$5.1 million in 2024, then surged by 142.42% to $2.2 million in 2025.
- Business Quant data shows MBRX's Change in Cash at $2.2 million in Q4 2025, -$854000.0 in Q3 2025, and -$159000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -185.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 427.25 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.94 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.42 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Moleculin Biotech | 3.37 Mn | 3.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.18 Mn |
| Sep 30, 2025 | -854,000.00 |
| Jun 30, 2025 | -159,000.00 |
| Mar 31, 2025 | 3.44 Mn |
| Dec 31, 2024 | -5.13 Mn |
| Sep 30, 2024 | -1.44 Mn |
| Jun 30, 2024 | -5.98 Mn |
| Mar 31, 2024 | -6.73 Mn |
| Dec 31, 2023 | -1.03 Mn |
| Sep 30, 2023 | -7.59 Mn |
| Jun 30, 2023 | -5.09 Mn |
| Mar 31, 2023 | -5.88 Mn |
| Dec 31, 2022 | -7.25 Mn |
| Sep 30, 2022 | -7.61 Mn |
| Jun 30, 2022 | -8.11 Mn |
| Mar 31, 2022 | -4.80 Mn |
| Dec 31, 2021 | -4.28 Mn |
| Sep 30, 2021 | -4.33 Mn |
| Jun 30, 2021 | -6.79 Mn |
| Mar 31, 2021 | 71.12 Mn |